Scurfin-Binding Peptides for Treg Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modulating the activity of regulatory T (Treg) lymphocytes are limited, particularly in effectively inhibiting their immunosuppressive effects without risking autoimmune diseases, as existing approaches either deplete these cells or non-specifically target cytokines, lacking specific inhibitors for Treg cells.
Innovation Solution
Development of peptides that bind to and inhibit the biological activity of scurfin, a crucial transcription factor for Treg lymphocytes, allowing for transient regulation or blocking of their immunosuppressive activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Treg lymphocytes are depleted to enhance immune response, then antitumor immunity is improved, but risk of autoimmune diseases increases
Solution Approach 1:
The patent extracts and targets the specific transcription factor scurfin (FOXP3) that is essential for Treg cell function. By using peptides that specifically bind to and inhibit scurfin, the invention selectively modulates Treg cell activity without depleting the cells themselves, thereby enhancing immune response while preserving immune tolerance and reducing autoimmune risk.
Solution Approach 2:
The patent introduces peptide molecules as intermediary substances that mediate between the therapeutic goal (enhancing immune response) and the safety constraint (avoiding autoimmunity). These peptides act as soluble inhibitors that temporarily block scurfin function, providing controlled modulation of Treg activity rather than complete depletion.
2Productivity
If Treg lymphocytes are depleted to control infection, then effector T response magnitude is improved, but loss of immune tolerance occurs
Solution Approach 1:
The patent extracts the specific molecular target (scurfin/FOXP3) within Treg cells and develops selective peptide inhibitors against it. This approach allows temporary and reversible inhibition of Treg function to enhance effector responses, while the presence of Treg cells is maintained to preserve immune tolerance mechanisms.
Solution Approach 2:
The patent employs dynamic modulation of Treg cell activity through peptide inhibition rather than static depletion. The peptide inhibitors provide temporary, controllable suppression of scurfin function, allowing the system to dynamically adjust between immune activation and tolerance maintenance based on therapeutic needs.
3Reliability
If scurfin activity is inhibited to block Treg function, then immunosuppressive effect is reduced, but specificity of targeting must be maintained
Solution Approach 1:
The patent extracts the specific amino acid sequence of scurfin (FOXP3 transcription factor) and designs peptides that complementarily bind to this specific target. This extraction of the molecular target enables highly specific inhibition of scurfin function while minimizing off-target effects on other cellular processes.
Solution Approach 2:
The patent creates synthetic peptide copies that mimic or complement the binding interface of scurfin. These peptide inhibitors are designed based on the known structure and sequence of scurfin, allowing specific recognition and binding to the target protein while maintaining high specificity for the intended molecular interaction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides effectively inhibit the immunosuppressive activity of Treg lymphocytes, providing a safer and more targeted approach to modulate their function, potentially enhancing antitumor responses and improving infectious disease control without inducing autoimmunity.
Implementation Method 1
peptides having the capacity to bind to scurfin and to their applications. The invention particularly relates to peptides inhibiting the biological activity of scurfin by means of their direct binding to said protein
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15. wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases. Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro-Phe-Phe-X (I)